ethyl 1-(3-methoxyphenyl)-1H-1,2,3-triazole-4-carboxylate | 1126635-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 1-(3-methoxyphenyl)-1H-1,2,3-triazole-4-carboxylate
• 英文别名: ethyl 1-(3-methoxyphenyl)triazole-4-carboxylate
• CAS: 1126635-91-3
• 化学式: C₁₂H₁₃N₃O₃
• 分子量: 247.254
• InChiKey: SDRVSRFISBRKEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 1-(3-methoxyphenyl)-1H-1,2,3-triazole-4-carboxylate 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 以97.9%的产率得到1-(3-methoxyphenyl)-1H-1,2,3-triazole-4-carboxylic acid
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinolinyl Triazole Carboxamide and Triazole Substituted Benzamide Analogues as σ₂ Receptor Ligands

  摘要：

  Two novel classes of compounds targeting the sigma-2 (sigma(2)) receptor were synthesized, and their bioactivities to binding sigma(1) and sigma(2) receptors were measured. Four novel triazole carboxamide analogues, 24d, 24e, 24f, and 39c, demonstrated high affinity and selectivity for the sigma(2) receptor. These data suggest C-11-labeled versions of these compounds may be potential sigma(2)-selective radiotracers for imaging the proliferative status of solid tumors.

  DOI：

  10.1021/jm5001453
• 作为产物：
  描述：

  间氨基苯甲醚 在 盐酸 、 bathophenanthrolinedispufonic acid disodium salt 、 copper(II) sulfate 、 sodium ascorbate 、 sodium nitrite 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 1-(3-methoxyphenyl)-1H-1,2,3-triazole-4-carboxylate
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinolinyl Triazole Carboxamide and Triazole Substituted Benzamide Analogues as σ₂ Receptor Ligands

  摘要：

  Two novel classes of compounds targeting the sigma-2 (sigma(2)) receptor were synthesized, and their bioactivities to binding sigma(1) and sigma(2) receptors were measured. Four novel triazole carboxamide analogues, 24d, 24e, 24f, and 39c, demonstrated high affinity and selectivity for the sigma(2) receptor. These data suggest C-11-labeled versions of these compounds may be potential sigma(2)-selective radiotracers for imaging the proliferative status of solid tumors.

  DOI：

  10.1021/jm5001453

文献信息

• Alkyl Propiolates Participated [3+2] Annulation for the Switchable Synthesis of 1,5‐ and 1,4‐Disubstituted 1,2,3‐Triazoles Containing Ester Side Chain
  作者：Shuo Cao、Yunyun Liu、Changfeng Hu、Chengping Wen、Jie‐Ping Wan

  DOI：10.1002/cctc.201801366

  日期：2018.11.7

  By means of a featured enamine activation, the alkyl propiolates have been successfully employed in the [3+2] annulation for the synthesis of 1,2,3‐triazoles. The synthesis of both 1,4‐ as well as the hardly available 1,5‐disubstituted 1,2,3‐triazoles can be selectively accessed by using tosyl azide and tosyl hydrazine as nitrogen source, respectively.

  通过特征性的烯胺活化，丙酸烷基酯已成功用于[3 + 2]环合中，用于合成1,2,3-三唑。通过分别使用甲苯磺酰甲苯磺酰基和甲苯磺酰肼作为氮源，可以选择性地获得1,4-以及几乎不可用的1,5-二取代的1,2,3-三唑的合成。
• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150353505A1

  公开（公告）日：2015-12-10

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了公式（I）的化合物或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如此定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗心血管，平滑肌，肿瘤，神经病理，自身免疫，纤维化和/或炎症性疾病的方法。
• Phthalazinones and isoquinolinones as rock inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10385026B2

  公开（公告）日：2019-08-20

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• US9926282B2
  申请人：——

  公开号：US9926282B2

  公开（公告）日：2018-03-27
• [EN] PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS<br/>[FR] PHTALAZINONES ET ISOQUINOLINONES EN TANT QU'INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014113620A2

  公开（公告）日：2014-07-24

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.